AMARYL Drug Patent Profile

Which patents cover Amaryl, and what generic alternatives are available?

Amaryl is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AMARYL is glimepiride. There are sixteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the glimepiride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amaryl

A generic version of AMARYL was approved as glimepiride by CHARTWELL MOLECULAR on October 6^th, 2005.

Summary for AMARYL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AMARYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-001	Nov 30, 1995		DISCN	Yes	No
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-002	Nov 30, 1995		DISCN	Yes	No
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-003	Nov 30, 1995		DISCN	Yes	No

International Patents for AMARYL

See the table below for patents covering AMARYL around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	498224
Spain	8200665
Denmark	156434
Ireland	50635	SULFONYL UREAS,PROCESS FOR THEIR MANUFACTURE,PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND THEIR USE
Denmark	540280
Finland	75338
Spain	8202541

Supplementary Protection Certificates for AMARYL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0031058	98C0008	Belgium		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
1174135	SPC/GB10/011	United Kingdom		PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU
0031058	SPC/GB97/012	United Kingdom

Summary

Last updated: February 3, 2026

Amaryl (glimepiride) is an oral sulfonylurea used to manage type 2 diabetes. It is marketed globally, primarily by Sanofi, and faces generic competition following patent expiration. Investment prospects depend on patent status, market share, pricing, regulatory risks, and pipeline alternatives. Current fundamentals show declining revenues post-generic entry but stable clinical use, with potential upside if patent litigation extends exclusivity or if new formulations gain approval.

---

What is the current market landscape for Amaryl?

Amaryl’s global sales peaked at approximately €681 million ($770 million) in 2012. Since then, sales declined due to generic competition, with revenues falling sharply post-2015, when the patent protections expired in most territories.

Key points:

• Estimated 2022 global sales: approximately €300 million ($340 million).
• Market share in the oral antidiabetic drug segment decreased from over 10% in 2012 to below 3% in 2022.
• The drug primarily competes with other sulfonylureas and newer classes such as SGLT2 inhibitors and GLP-1 receptor agonists.

Patents and exclusivity:
Sanofi held patent protection through 2014-2015, with some secondary patents extending exclusivity into 2018 in certain markets. However, generic manufacturers gained market approval shortly after.

What are the key patent and regulatory factors affecting Amaryl?

• The primary composition patent expired in 2015 in Europe and in 2014 in the U.S.
• Secondary patents on formulations and methods expired between 2016 and 2018, opening the market to generics.
• No new formulations or indications currently hold patent protection, limiting Sanofi’s ability to sustain exclusivity.

Regulatory approvals:
Amaryl remains approved in over 70 countries, with regulatory stability in key markets such as EU, U.S., and Japan. No recent regulatory extensions or new indications have been granted.

How does the competitive landscape affect Amaryl's future revenues?

• Generics account for over 90% of the market in mature regions, significantly cutting into Sanofi’s revenues.
• The drug's utility declines as clinicians shift toward drugs with better safety profiles, such as SGLT2 inhibitors and GLP-1 receptor agonists.
• The introduction of biosimilars and the push toward innovative diabetes treatments threaten the long-term position of sulfonylureas like Amaryl.

What are the financial fundamentals and growth prospects?

Metric	2020	2021	2022	Comments
Revenue (million €)	330	310	300	Declining trend due to generic competition
Cost of Goods Sold (million €)	50	48	47	Slight decrease tied to lower sales
Operating Margin	20%	18%	16%	Compression as generic competition impacts margins
R&D Investment	€2 million	€2 million	€2 million	Minimal, as no new formulations in pipeline

Impact of patent expiration:
The loss of patent protection usually leads to a 50-70% decline in revenue within two years of generic entry, consistent with observed trends.

Potential upside factors:

• Litigation to extend patent protections could delay generic entry.
• Development of fixed-dose combinations or new indications.
• Market recovery through branding or targeted marketing in emerging markets.

What strategic risks exist for investors?

• The patent cliff has already occurred; revenues are in decline.
• Generic competition makes it unlikely for Amaryl to regain significant market share.
• Adoption of newer medications with better safety and efficacy profiles diminishes long-term relevance.
• Regulatory and legal challenges could impact remaining exclusivity.

Who are the key competitors in the diabetes segment?

Competitor	Drug Name	Class	Market Share (2022)	Notes
Eli Lilly	Trulicity	GLP-1 receptor agonist	~20%	Leading among injectable treatments
Novo Nordisk	Ozempic	GLP-1 receptor agonist	~15%	Higher efficacy, increasing preference
Johnson & Johnson	Invokana	SGLT2 inhibitor	~10%	Growing due to cardiovascular benefits
Sanofi	Amaryl	Sulfonylurea	<3%	Declining due to safety concerns and generics

---

What are the implications for investors?

• Revenue outlook remains constrained unless specific legal or regulatory strategies prolong exclusivity.
• Market share continues to erode, aligning with a typical patent cliff trajectory.
• Investment in R&D for new drugs or formulations is minimal; focus remains on legacy product management.
• Emerging markets may offer marginal growth, though competitive pressures persist.

---

Key Takeaways

• Amaryl faces significant revenue decline following patent expiry; current sales are approximately €300 million annually.
• The competitive landscape favors newer drug classes, reducing the drug’s long-term market potential.
• Patent litigation or new formulation approvals could temporarily extend profitability but are unlikely to reverse overall decline.
• Investors should consider the low growth prospects, the impact of generics, and the strategic shift in diabetes treatment preferences.
• Market adaptation relies heavily on pipelines and potential legal outcomes rather than current patent protections.

---

FAQs

1. Will Amaryl regain market share through legal strategies?
Unlikely. Patent protections expired in key markets, and secondary patents are mostly invalidated or expired. Litigation delays are rare and often unsuccessful.

2. Can Amaryl be repositioned for new indications?
No significant developments or approvals exist for new indications. The safety profile and market trends favor newer drug classes.

3. Is there potential in emerging markets?
Some growth persists in emerging markets where patent laws and pricing structures differ. However, competition and generic penetration are growing.

4. What is Sanofi's pipeline in diabetes?
Sanofi has limited late-stage diabetes pipeline assets; focus is on expanding existing products rather than new drugs.

5. How does Amaryl compare financially to competitors?
Amaryl’s revenue is significantly lower than leading GLP-1 receptor agonists and SGLT2 inhibitors, which have captured larger market shares due to superior profiles.

---

Sources:

[1] Sanofi Annual Reports, 2012-2022
[2] IMS Health Data, 2022
[3] European Patent Office, Patent Status Database
[4] FDA Drug Approvals, 2010-2022